ABSTRACT The COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an unprecedented event requiring frequent adaptation to changing clinical circumstances. Convalescent immune plasma (CIP) is a promising treatment that can be mobilized rapidly in a pandemic setting. We tested whether administration of SARS-CoV-2 CIP at hospital admission could reduce the rate of ICU transfer or 28-day mortality or alter levels of specific antibody responses before and after CIP infusion. In a single-arm phase II study, patients >18 years-old with respiratory symptoms with confirmed COVID-19 infection who were admitted to a non-ICU bed were administered two units of CIP within 72 h of admission. Levels of SARS-CoV-2 detected by PCR in the respiratory tract and circulating anti-SARS-CoV-2 antibody titers were sequentially measured before and after CIP transfusion. Twenty-nine patients were transfused high titer CIP and 48 contemporaneous comparable controls were identified. All classes of antibodies to the three SARS-CoV-2 target proteins were significantly increased at days 7 and 14 post-transfusion compared with baseline ( P < 0.01). Anti-nucleocapsid IgA levels were reduced at day 28, suggesting that the initial rise may have been due to the contribution of CIP. The groups were well-balanced, without statistically significant differences in demographics or co-morbidities or use of remdesivir or dexamethasone. In participants transfused with CIP, the rate of ICU transfer was 13.8% compared to 27.1% for controls with a hazard ratio 0.506 (95% CI 0.165–1.554), and 28-day mortality was 6.9% compared to 10.4% for controls, hazard ratio 0.640 (95% CI 0.124–3.298). IMPORTANCE Transfusion of high-titer CIP to non-critically ill patients early after admission with COVID-19 respiratory disease was associated with significantly increased anti-SARS-CoV-2 specific antibodies (compared to baseline) and a non-significant reduction in ICU transfer and death (compared to controls). This prospective phase II trial provides a suggestion that the antiviral effects of CIP from early in the COVID-19 pandemic may delay progression to critical illness and death in specific patient populations. This study informs the optimal timing and potential population of use for CIP in COVID-19, particularly in settings without access to other interventions, or in planning for future coronavirus pandemics.
【저자키워드】 COVID-19, convalescent plasma, antibodies, SARS-CoV-2, Respiratory failure, 【초록키워드】 Dexamethasone, Treatment, Critical illness, coronavirus, pandemic, Trial, antibody, COVID-19 pandemic, Antibody Response, 28-day mortality, Remdesivir, antiviral effects, progression, severe acute respiratory syndrome Coronavirus, anti-SARS-CoV-2, immune, ICU, Antiviral effect, PCR, Critically ill, anti-SARS-CoV-2 antibody, COVID-19 infection, Respiratory disease, Patient, Control, death, Pandemics, co-morbidity, plasma, Hospital admission, respiratory tract, transfusion, respiratory, group, Admission, Critical, co-morbidities, Antibody titers, administration, respiratory symptoms, demographics, Planning, acute respiratory syndrome, 95% CI, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, hazard ratio, morbidities, non-ICU, statistically significant difference, transfer, participant, Confirmed COVID-19 infection, respiratory symptom, circulating, target proteins, target protein, suggestion, non-critically ill patients, Administered, Alter, populations, controls, single-arm, initial, significantly increased, tested, caused, specific antibody, reduced, provide, comparable, reduce, reduction in, Level, IgA level, baseline, non-critically ill patient, transfused, with COVID-19, 【제목키워드】 Phase 2, profile, illness, Preventing,